Abstract Library

#3354 Cancer associated fibroblasts induce proliferation and therapeutic resistance in neuroendocrine tumors through STAT3 activation

Introduction: Cancer-associated fibroblasts (CAF) have been identified as relevant contributors to cancer progression and drug resistance in many tumors. Although neuroendocrine tumors (NET) are often associated with a strong stromal reaction, no study has addressed whether CAF are involved in progression and therapeutic resistance in NET.

Conference:

Presenting Author:

Authors: Amin T, Viol F, Fahl M, Eggers C, Awwad F,

Keywords: neuroendocrine tumor, cancer associated fibroblasts, NT-3, cell lines,

#2270 Development of Pre-Clinical NEN Models – Limitations and Opportunities

Introduction: Pre-clinical research in neuroendocrine neoplasia (NEN) has long been impaired by the paucity of NET and NEC cell lines. Furthermore, established models have not been widely available or displayed unusual features (eg. p53 and ras mutations, high proliferation rate).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Schrader J

Authors: Schrader J, Benten D, Unrau L, Fahl M, Eggers C,

Keywords: cell line,

#1869 Synergistic Effects of Combining Hsp90 and PI3K Inhibitors with Everolimus in Pancreatic Neuroendocrine Tumors

Introduction: The development of the first molecular targeted therapies for neuroendocrine tumors (NET) was a milestone in the treatment of patient. Nevertheless, these therapies eventually fail and patients become resistant to the treatment. One way of escaping this dilemma might be the combination of targeted drugs to prevent resistance development.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Schrader J

Authors: Weissmann V, Benten D, Fahl M, Eggers C, Izbicki J,

Keywords: targeted therapies, mTOR,

#1867 Establishment of the First Well-Differentiated in Vivo Human Pancreatic Neuroendocrine Tumor Model

Introduction: The development of new therapeutic strategies for cancer patients relies on the in vitro and in vivo testing of novel substances in the pre-clinical setting. So far, this has not been possible for pancreatic neuroendocrine tumors (pNET) due to lack of suitable animal models resembling the disease course in human patients.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Schrader J, Unrau L, Stahl F, Eggers C, Fahl M,

Keywords: pNET, insulinoma, SSTR,

#1573 Regulation of Neuroendocrine Differentiation by Growth Factor Induced Proliferation in a Well-differentiated Pancreatic Neuroendocrine Tumor Cell Line

Introduction: The regulation of neuroendocrine differentiation in NET tumor cells is poorly understood. Clinical experience suggests a correlation between proliferation and neuroendocrine de-differentiation.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Schrader J

Authors: Behrang Y, Benten D, Fahl M, Eggers C, Perez D,

Keywords: cell line, differentiation,